title: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA.
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: Stephen
authors.initials: S
authors.lastname: Hanauer
authors.forename: Edward V
authors.initials: EV
authors.lastname: Loftus
authors.forename: William J
authors.initials: WJ
authors.lastname: Tremaine
authors.forename: Sunanda
authors.initials: S
authors.lastname: Kane
authors.forename: Russell
authors.initials: R
authors.lastname: Cohen
authors.forename: Karen
authors.initials: K
authors.lastname: Hanson
authors.forename: Therese
authors.initials: T
authors.lastname: Johnson
authors.forename: Debra
authors.initials: D
authors.lastname: Schmitt
authors.forename: Resa
authors.initials: R
authors.lastname: Jeche
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D010865:Pilot Projects; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab